tqc2731
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Jun 25, 2021 (NCT04923607)
Timeline
Indications
Mechanism of action
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07107256 | Phase 3 | Sep 25, 2025 | Government of China |
| NCT06829784 | Phase 3 | Mar 31, 2025 | Government of China |
| NCT06707883 | Phase 2 | Jan 31, 2025 | Government of China |
| NCT06451640 | Phase 2 | Jul 4, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06036927 | Phase 2 | Oct 31, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05472324 | Phase 2 | Sep 23, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04923607 | Phase 1 | Jun 25, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 4 | 4 | 2 | 2021 |
| Government of China | Government | 3 | 3 | 2 | 2025 |
2 organizations
Page 1 / 1